20 results
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
25 Oct 23
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:24pm
®, the annual meeting of the Obesity Society. The presentation highlighted the previously reported safety, tolerability, and weight loss findings
PRE 14A
VKTX
Viking Therapeutics Inc
17 Apr 23
Preliminary proxy
5:04pm
University in Scotland in 1982, where he was a Royal Society Research Fellow, and his B.V.M.S. (equivalent to a D.V.M.) in 1979 from Glasgow University
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
26 Oct 22
Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:32pm
from this program, which were presented last November at the annual meeting of The Obesity Society, demonstrated that GIP receptor activity improved
8-K
EX-99.1
7kxhye 2zc35
27 Jul 22
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
w9ule vua414atn90r
27 Apr 22
Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:44pm
8-K
EX-99.1
pzte2czl
9 Feb 22
Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
4:15pm
8-K
EX-99.1
o3f n7r1dfxuqx28oz
3 Nov 21
Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:10pm
8-K
EX-99.1
q5v y9u41d954t2jguk
13 Mar 19
Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
4:12pm
8-K
EX-99.1
dwo8dolyz
7 Nov 18
Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
12:00am
8-K
EX-99.1
tdnfztv
9 Aug 18
Viking Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
12:00am
424B4
arkmwgxot z4c
8 Apr 16
Prospectus supplement with pricing info
12:00am
10-K
9oheo8yg8
8 Mar 16
Annual report
12:00am
- Prev
- 1
- Next